Pfizer Inc.

NYSE:PFE  
39.58
+0.38 (+0.98%)
4:03:58 PM EDT: $39.50 -0.08 (-0.19%)
Products

U.S. FDA Expands Approval Of Pfizer’S LORBRENA For ALK-Positive Metastatic Lung Cancer

Published: 03/04/2021 01:29 GMT
Pfizer Inc. (PFE) - U.S. FDA Expands Approval of Pfizer’s Lorbrena® As First-line Treatment for Alk-positive Metastatic Lung Cancer.
Pfizer - Approval is Based on Crown Trial, Which Showed a 72% Reduction in Risk of Progression Or Death for Treatment With Lorbrena Versus.
Xalkori.